At IPI, 2022 was synonymous with growth and progress. The Institute recruited young researchers with astonishing talents who’ve worked together to enhance each others’ expertise and improve IPI’s high-throughput platform.
Together, we’ve produced our first set of affinity reagents and entered partnerships to help sell and distribute these reagents soon. And, under the guidance of our new president and CEO, we’ve renewed our educational focus and determination to disseminate protein science knowledge to the biomedical community. We’re proud of this year of progress at IPI and excited to continue to advance our understanding of human biology and disease in 2023.
As the world struggled to live in and through a seeming “forever pandemic,” 2021 was a year that demanded global resilience.
At IPI, we fought back, digging deep into expertise and mission to find ways to work, rebuild and connect. We hired record numbers of new staff, redoubled our efforts to create fit-for-purpose antibodies and embarked on new frontiers in antigen and antibody discovery. For us, 2021 was a time of renewal.